Comparison of Avid Bioservices Inc. (CDMO) and ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

As Biotechnology businesses, Avid Bioservices Inc. (NASDAQ:CDMO) and ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), are affected by compare. This especially applies to their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Avid Bioservices Inc. 43.49M 5.11 16.11M -0.29 0.00
ACADIA Pharmaceuticals Inc. 237.90M 14.70 276.20M -2.09 0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Avid Bioservices Inc. and ACADIA Pharmaceuticals Inc.

Profitability

Table 2 shows Avid Bioservices Inc. and ACADIA Pharmaceuticals Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Avid Bioservices Inc. -37.04% -20.3% -13.3%
ACADIA Pharmaceuticals Inc. -116.10% -79.7% -68.1%

Risk and Volatility

Avid Bioservices Inc. is 172.00% more volatile than S&P 500 because the company has a beta of 2.72. ACADIA Pharmaceuticals Inc. has a 3.1 beta and it is 210.00% more volatile than S&P 500.

Liquidity

The current Quick Ratio of Avid Bioservices Inc. is 1.9 while its Current Ratio is 2.3. Meanwhile, ACADIA Pharmaceuticals Inc. has a Current Ratio of 6.4 while its Quick Ratio is 6.3. ACADIA Pharmaceuticals Inc. is better positioned to pay off its short-term and long-term debts than Avid Bioservices Inc.

Analyst Recommendations

Avid Bioservices Inc. and ACADIA Pharmaceuticals Inc. Recommendations and Ratings are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Avid Bioservices Inc. 0 0 0 0.00
ACADIA Pharmaceuticals Inc. 0 0 5 3.00

The upside potential is 152.53% for Avid Bioservices Inc. with average price target of $10. Competitively the average price target of ACADIA Pharmaceuticals Inc. is $43, which is potential 77.25% upside. Based on the analysts opinion we can conclude, Avid Bioservices Inc. is looking more favorable than ACADIA Pharmaceuticals Inc.

Institutional & Insider Ownership

Avid Bioservices Inc. and ACADIA Pharmaceuticals Inc. has shares owned by institutional investors as follows: 52.3% and 96.1%. Insiders owned 11.62% of Avid Bioservices Inc. shares. Insiders Competitively, owned 0.1% of ACADIA Pharmaceuticals Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Avid Bioservices Inc. -19.55% -16.16% -0.28% -28.69% -1.1% -12.68%
ACADIA Pharmaceuticals Inc. -0.8% 1.69% 16.27% 37.54% 35.53% 60.42%

For the past year Avid Bioservices Inc. has -12.68% weaker performance while ACADIA Pharmaceuticals Inc. has 60.42% stronger performance.

Summary

Avid Bioservices Inc. beats ACADIA Pharmaceuticals Inc. on 7 of the 12 factors.

Avid Bioservices, Inc., a biologics contract development and manufacturing company, focuses on the development and current Good Manufacturing Practices (cGMP) manufacture of biopharmaceutical products derived from mammalian cell culture. It provides a range of process development, cGMP clinical, and commercial manufacturing services for the biotechnology and biopharmaceutical industries. The company produces monoclonal antibodies and recombinant proteins in batch, fed-batch, and perfusion modes; and offers services, including cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission, and support. It also provides various process development services, such as cell line development and optimization, cell culture and feed optimization, analytical methods development, and product characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was founded in 1981 and is headquartered in Tustin, California.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.